DOJ Accuses Regeneron of Fraudulent Drug Pricing for Eylea
Wednesday, 10 April 2024, 22:14
Regeneron Fraud Allegations for Eylea
The Department of Justice accused Regeneron Pharmaceuticals Inc. of fraudulent practices related to the pricing of its blockbuster drug Eylea.
Boosting Sales through Fraudulent Practices
The accusations suggest that Regeneron's pricing strategies for Eylea may have been unethical, potentially influencing sales figures.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.